St Cloud Regional Medical Center | |
2906 17th Street, Saint Cloud, Florida 34769 | |
(407) 498-3432 | |
Name | St Cloud Regional Medical Center |
---|---|
Type | Acute Care Hospital |
Location | 2906 17th Street, Saint Cloud, Florida |
Ownership | Proprietary |
Emergency Services | Yes |
Medicare ID (CCN) | 100302 |
NPI Number | 1164478442 |
Organization Name | OSCEOLASC LLC |
Doing Business As | ST CLOUD REGIONAL MEDICAL CENTER |
Address | 2906 17th St, Saint Cloud, FL 34769 |
Hospital Type | General Acute Care Hospital |
Phone Number | 407-832-2135 |
News Archive
VBL Therapeutics, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer.
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.
The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).
Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis as physician researchers.
› Verified 9 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
VBL Therapeutics, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer.
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.
The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).
Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis as physician researchers.
› Verified 9 days ago
St Cloud Regional Medical Center Acute Care Hospital Location: 2906 17th Street, Saint Cloud, Florida 34769 Phone: (407) 498-3432 | |
Blackberry Center Psychiatric Hospital Location: 91 Beehive Cir, Saint Cloud, Florida 34769 Phone: (321) 805-5090 |